CasZyme
Caszyme is a pioneering biotechnology company specializing in CRISPR gene editing technology. Founded in 2017 in Vilnius, Lithuania, it develops innovative gene editing tools and solutions across various sectors including healthcare, agriculture, diagnostics, and industrial biotech. With a mission to leverage CRISPR to create a healthier, equitable, and sustainable world, Caszyme collaborates with global partners and continuously advances its platform through research, development, and strategic projects. The company values courage, curiosity, collaboration, caring, and commitment to change, aiming to deliver world-class CRISPR solutions tailored to diverse industrial needs.
Industries
Nr. of Employees
small (1-50)
CasZyme
Patents
Products
Protein thermostability prediction tool (TemStaPro — publication)
A published computational method using deep learning and protein language models to predict protein thermostability from sequence, validated against experimental data for effector proteins.
CRISPR-based SARS-CoV-2 variant detection prototype
A prototype detection system for SARS-CoV-2 variants using RNA-guided nucleases and isothermal amplification developed and validated during a funded research project.
Protein thermostability prediction tool (TemStaPro — publication)
A published computational method using deep learning and protein language models to predict protein thermostability from sequence, validated against experimental data for effector proteins.
CRISPR-based SARS-CoV-2 variant detection prototype
A prototype detection system for SARS-CoV-2 variants using RNA-guided nucleases and isothermal amplification developed and validated during a funded research project.
Services
Identification and biochemical/functional profiling of novel RNA-guided nucleases for use in research, diagnostics, therapeutics and industrial applications.
Design and synthesis of mRNA templates with early-stage quality control and potency testing to support gene-editor expression optimization in discovery projects.
Rational design and directed evolution campaigns to improve nuclease activity, specificity and other desired biochemical traits.
Design, prototyping and analytical validation of CRISPR-based nucleic-acid detection assays, including SNP detection and pathogen testing workflows with isothermal amplification and direct-sample methods.
Experimental verification and optimization of gene-editing outcomes when delivering editing agents as RNP complexes, mRNA or DNA, across cellular contexts.
Management and execution of collaborative R&D projects, grant-backed consortia participation, and licensing/partnering to translate discoveries into applications.
Identification and biochemical/functional profiling of novel RNA-guided nucleases for use in research, diagnostics, therapeutics and industrial applications.
Design and synthesis of mRNA templates with early-stage quality control and potency testing to support gene-editor expression optimization in discovery projects.
Rational design and directed evolution campaigns to improve nuclease activity, specificity and other desired biochemical traits.
Design, prototyping and analytical validation of CRISPR-based nucleic-acid detection assays, including SNP detection and pathogen testing workflows with isothermal amplification and direct-sample methods.
Experimental verification and optimization of gene-editing outcomes when delivering editing agents as RNP complexes, mRNA or DNA, across cellular contexts.
Management and execution of collaborative R&D projects, grant-backed consortia participation, and licensing/partnering to translate discoveries into applications.
Expertise Areas
- CRISPR nuclease discovery and characterization
- Protein engineering and directed evolution
- mRNA synthesis and optimization
- CRISPR-based diagnostic assay development
Key Technologies
- RNA-guided nucleases (CRISPR-Cas family)
- Metagenomic sequence mining
- Bioinformatics and structural protein analysis
- Directed evolution
News & Updates
Event on May 6, 2025, showcasing Caszyme's participation at ASGCT 2025.
Event on March 28, 2025, where Caszyme participated in the Global Innovation Summit.
Event on March 14, 2025, featuring Caszyme at the Advanced Therapies Congress.
Event on March 4, 2025, with Caszyme's participation in the World Agri-Tech Innovation Summit.
Event on February 14, 2025, where Caszyme attended the European Life Sciences CEO Forum.
Scientific publication on October 21, 2022, about a new family of CRISPR-type V nucleases.
Event on May 6, 2025, showcasing Caszyme's participation at ASGCT 2025.
Event on March 28, 2025, where Caszyme participated in the Global Innovation Summit.
Event on March 14, 2025, featuring Caszyme at the Advanced Therapies Congress.
Event on March 4, 2025, with Caszyme's participation in the World Agri-Tech Innovation Summit.
Event on February 14, 2025, where Caszyme attended the European Life Sciences CEO Forum.
Scientific publication on October 21, 2022, about a new family of CRISPR-type V nucleases.